Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies

Clostridioides difficile infection (CDI) and recurrent CDI (rCDI) remain associated with a reduction in the patients’ quality of life and with increased healthcare costs. Bezlotoxumab is a monoclonal antibody against toxin B of C. difficile, approved for prevention of rCDI. In this narrative review,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Infect Dis Ther
Auteurs principaux: Giacobbe, Daniele Roberto, Dettori, Silvia, Di Bella, Stefano, Vena, Antonio, Granata, Guido, Luzzati, Roberto, Petrosillo, Nicola, Bassetti, Matteo
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7452994/
https://ncbi.nlm.nih.gov/pubmed/32632582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-020-00314-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires